CANF · Can-Fite BioPharma Ltd. · Metrics
Market Cap
$5.73M
Shares
3.03M
Volume · Oct 22
14.12K
Avg daily vol (3M)
358.4K
CANF metrics
57 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.89
Market cap
$5.73M
Price action
20 metricsPrice change (1W)
-2.1%
Price change (30D)
-15.3%
Price change (3M)
-42.7%
Price change (6M)
-36.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
100.9%
Annualized volatility (3M)
75.2%
Beta
0.7
RSI (14D)
33.3
Price vs SMA 50
-24.5%
Price vs SMA 200
-42.7%
Avg volume (3M)
358,396
Relative volume
0.0
Average dollar volume
$855,793
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
3.03M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
14.1×
reciprocal yield 7.1%
P / book
1.2
reciprocal yield 84.8%
FCF yield
-166.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-166.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-2,403.0%
Trailing 12 months
Net margin
-2,358.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$9.73M
Net income (TTM)
−$9.55M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-2,348.9%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-39.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$405,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+127.0%
Year over year · more shares
Revenue CAGR (3Y)
-20.6%
Revenue CAGR (5Y)
-11.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-196.8%
Return on assets
-118.6%
Debt / equity
—
Current ratio
3.6
EBITDA (TTM)
−$9.73M
Free cash flow (TTM)
−$9.51M
Quick ratio
3.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.98M
Total assets
$8.05M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$9.51M
Capital expenditures (TTM)
$2,000
R&D (TTM)
$7.12M
SG&A (TTM)
—
Stock compensation (TTM)
$181,000
R&D / revenue
1,756.8%
Stock compensation / revenue
44.7%
Ownership (13F)
9 metrics13F filers
8
13F filer change QoQ
-6
Institutional ownership
1.7%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-72.1%
Holder tenure
5.9
Price vs estimated holder cost
-98.9%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
1.8%
Latest settlement · 1.2 days to cover
Days to cover
1.2d
Short-squeeze score
39 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—